恒瑞医药

- 600276

-

-  -

-
昨收盘:- 今开盘:- 最高价:- 最低价:-
市值:-亿元 流通:- 成交:-手 换手:-
单位:元   
恒瑞医药(600276) 利润表
报告期2008-06-302008-03-312007-12-312007-09-302007-06-30
一、主营业务收入1,197,483,048598,494,5711,959,660,1221,387,117,063900,151,179
折扣与折让00000
主营业务收入净额1,197,483,048598,494,5711,959,660,1221,387,117,063900,151,179
主营业务成本220,632,89093,767,082330,374,168236,931,896156,659,095
主营业务税金及附加18,817,2309,884,56931,167,65922,202,79814,501,974
二、主营业务利润958,032,928494,842,9211,598,118,2941,127,982,369728,990,110
其他业务利润00000
存货跌价损失00000
营业费用491,673,514226,593,560798,094,913535,317,502374,420,889
管理费用120,224,38783,778,507406,229,649265,080,981175,048,851
财务费用4,582,0922,426,7403,901,530912,665197,299
三、营业利润337,012,719176,904,865366,799,993320,794,930172,944,007
投资收益19,999,43915,254,90238,847,0557,726,9457,726,945
补贴收入00000
营业外收入555,299161,2994,616,8212,660,681253,475
营业外支出3,116,158751800,083169,09282,333
以前年度损益调整00000
营业外收支净额-2,560,859160,5493,816,7382,491,589171,143
四、利润总额255,622,614102,146,773511,459,509341,554,405187,765,136
所得税58,892,86625,768,88492,928,46984,738,15231,510,580
财政返还00000
少数股东权益4,912,3052,090,0185,609,7527,356,9732,499,168
购买日前净利润00000
未确认的投资损失00000
五、净利润191,817,44274,287,871412,921,287249,459,281153,755,388
年初未分配利润00000
调整以前年度损益00000
盈余公积转入00000
住房周转金转入00000
其他转入00000
六、可分配利润00000
提取法定盈余公积00000
提取法定公益金00000
职工奖金福利00000
提取储备基金00000
提取企业发展基金00000
七、可供股东分配的利润00000
应付优先股股利00000
提取任意盈余公积金00000
应付普通股股利00000
转作股本的普通股股利00000
八、未分配利润00000
恒瑞医药(600276) 利润表
报告期2007-03-312006-12-312006-09-302006-06-302006-03-31
一、主营业务收入401,912,7371,422,456,9051,039,422,066670,855,674333,481,132
折扣与折让00000
主营业务收入净额401,912,7371,422,456,9051,039,422,066670,855,674333,481,132
主营业务成本60,858,609266,339,173190,243,509124,933,26060,328,528
主营业务税金及附加6,635,06922,608,72316,543,29210,541,1955,326,008
二、主营业务利润334,419,0591,133,509,008832,635,265535,381,218267,826,596
其他业务利润0999,202709,745448,152299,323
存货跌价损失00000
营业费用152,014,999562,557,966400,711,864260,063,127126,753,652
管理费用73,751,597300,882,076221,033,923135,599,46864,504,869
财务费用-1,202,617-531,892-1,631,295-109,978-551,875
三、营业利润109,855,079271,600,060213,230,519140,276,75377,419,272
投资收益200,90018,150,378240,476251,119251,119
补贴收入00000
营业外收入77,898347,688341,88810,00010,000
营业外支出38,514802,773721,234108,3400
以前年度损益调整00000
营业外收支净额39,384-455,085-379,346-98,34010,000
四、利润总额109,566,829289,295,352213,091,649140,429,53277,680,391
所得税35,533,90284,392,58258,596,37533,851,66427,584,750
财政返还00000
少数股东权益613,995-1,745,027-1,520,211-939,747-1,187,732
购买日前净利润00000
未确认的投资损失00000
五、净利润73,418,932206,647,797156,015,485107,517,61551,283,373
年初未分配利润0303,174,0760303,174,076247,058,236
调整以前年度损益00000
盈余公积转入00000
住房周转金转入00000
其他转入00000
六、可分配利润0509,821,8730410,691,691298,341,608
提取法定盈余公积020,664,780000
提取法定公益金00000
职工奖金福利00000
提取储备基金00000
提取企业发展基金00000
七、可供股东分配的利润0489,157,0930410,691,691298,341,608
应付优先股股利00000
提取任意盈余公积金00000
应付普通股股利056,115,840056,115,8400
转作股本的普通股股利00000
八、未分配利润0433,041,2530354,575,851298,341,608
恒瑞医药(600276) 利润表
报告期2005-12-312005-09-302005-06-302005-03-312004-12-31
一、主营业务收入1,179,259,558877,084,597578,158,248290,450,6071,145,143,619
折扣与折让00000
主营业务收入净额1,179,259,558877,084,597578,158,248290,450,6071,145,143,619
主营业务成本229,908,675149,259,33597,702,30239,655,715286,318,825
主营业务税金及附加19,184,81314,684,5219,674,0144,936,77417,554,005
二、主营业务利润930,166,070713,140,741470,781,932245,858,118841,270,789
其他业务利润11,315,9838,088,2047,439,5255,579,2513,725,449
存货跌价损失00000
营业费用475,995,119390,663,046259,842,784134,491,047430,681,738
管理费用239,663,385155,058,300103,099,85653,810,191226,649,367
财务费用-78,556-357,503-234,695-48,2909,875,352
三、营业利润225,902,105175,865,102115,513,51163,184,420177,789,782
投资收益0000389,389
补贴收入00003,920,000
营业外收入220,771172,27150,3426,700252,695
营业外支出5,418,9281,541,14770,00070,0009,694,823
以前年度损益调整00000
营业外收支净额-5,198,157-1,368,876-19,658-63,300-9,442,128
四、利润总额220,703,948174,496,226115,493,85363,121,120172,657,042
所得税60,631,26145,891,60041,635,06224,860,72151,341,575
财政返还00000
少数股东权益-2,149,370-1,276,412-2,496,256-1,553,600-1,305,028
购买日前净利润00000
未确认的投资损失00000
五、净利润162,222,058129,881,03876,355,04839,813,999122,620,495
年初未分配利润224,410,8300224,410,8300149,899,890
调整以前年度损益00000
盈余公积转入00000
住房周转金转入00000
其他转入00001,921,744
六、可分配利润386,632,8870300,765,8770274,442,129
提取法定盈余公积16,222,20600012,262,049
提取法定公益金16,222,20600012,262,049
职工奖金福利00000
提取储备基金00000
提取企业发展基金00000
七、可供股东分配的利润354,188,4760300,765,8770249,918,030
应付优先股股利00000
提取任意盈余公积金00000
应付普通股股利51,014,400051,014,400025,507,200
转作股本的普通股股利00000
八、未分配利润303,174,0760249,751,4770224,410,830
恒瑞医药(600276) 利润表
报告期2004-09-302004-06-302004-03-312003-12-312003-09-30
一、主营业务收入891,788,555514,577,177245,112,1411,050,352,312760,880,018
折扣与折让00000
主营业务收入净额891,788,555514,577,177245,112,1411,050,352,312760,880,018
主营业务成本218,315,93686,984,46842,762,958348,193,902263,359,848
主营业务税金及附加13,498,5788,252,9603,819,03913,385,6809,640,013
二、主营业务利润659,974,042419,339,748198,530,144688,772,729487,880,157
其他业务利润3,281,7531,753,385-24,8753,987,2543,971,349
存货跌价损失00000
营业费用393,559,138236,052,116110,047,104339,859,487243,235,876
管理费用139,915,84996,788,11038,560,188198,346,513138,219,680
财务费用7,201,7385,682,1062,931,67916,892,32512,288,200
三、营业利润122,579,07082,570,80346,966,298137,661,65998,107,751
投资收益-401,013-10,104,7792,6432,479,02342,180
补贴收入00013,771,045311,046
营业外收入251,54539,94813,225119,802352,579
营业外支出4,539,2391,962,695909,1833,336,6681,632,073
以前年度损益调整00000
营业外收支净额-4,287,694-1,922,747-895,958-3,216,867-1,279,494
四、利润总额117,890,36370,543,27646,072,984150,694,86197,181,482
所得税24,785,44517,627,33915,344,10958,490,05037,657,241
财政返还00000
少数股东权益2,416,2331,511,517-220,941-2,315,184-1,957,897
购买日前净利润00000
未确认的投资损失00000
五、净利润90,688,68551,404,42030,949,81694,519,99561,482,138
年初未分配利润0151,821,6340100,044,05674,536,856
调整以前年度损益00000
盈余公积转入00000
住房周转金转入00000
其他转入00040,42840,428
六、可分配利润0203,226,0540194,604,478136,059,421
提取法定盈余公积0009,598,6940
提取法定公益金0009,598,6940
职工奖金福利00000
提取储备基金00000
提取企业发展基金00000
七、可供股东分配的利润0203,226,0540175,407,090136,059,421
应付优先股股利00000
提取任意盈余公积金00000
应付普通股股利025,507,200025,507,2000
转作股本的普通股股利00000
八、未分配利润0177,718,8540149,899,890136,059,421
恒瑞医药(600276) 利润表
报告期2003-06-302003-03-312002-12-312002-09-302002-06-30
一、主营业务收入496,021,562222,771,972756,025,462546,911,569358,278,188
折扣与折让00000
主营业务收入净额496,021,562222,771,972756,025,462546,911,569358,278,188
主营业务成本183,507,72273,539,420278,596,637224,291,534157,087,522
主营业务税金及附加5,820,8822,488,2339,282,9876,911,1494,397,263
二、主营业务利润306,692,958146,744,320468,145,838315,708,886196,793,403
其他业务利润2,981,631295,1342,211,627975,3663,543,983
存货跌价损失00000
营业费用145,174,15477,883,197234,069,135134,848,68576,338,174
管理费用97,207,81131,688,337117,266,10484,620,38354,206,579
财务费用8,159,6253,586,76312,711,49712,195,2296,405,057
三、营业利润59,132,99833,881,158106,310,72985,019,95563,387,575
投资收益42,18004,282,7501,443,5781,402,778
补贴收入0311,0454,090,0003,098,000715,000
营业外收入89,22739,394373,365256,860125,603
营业外支出1,216,877452,9304,547,8182,344,998868,832
以前年度损益调整00000
营业外收支净额-1,127,651-413,536-4,174,4530-743,228
四、利润总额58,047,52733,778,668110,509,02687,473,39564,762,124
所得税26,143,26111,147,13931,236,83424,901,17617,406,358
财政返还00000
少数股东权益-3,597,55275,078318,195635,204293,620
购买日前净利润00000
未确认的投资损失00000
五、净利润35,501,81822,556,45178,953,99761,937,01547,062,146
年初未分配利润74,536,856085,010,525085,010,525
调整以前年度损益00000
盈余公积转入00000
住房周转金转入00000
其他转入00-4,408,5250-4,408,525
六、可分配利润110,038,6740159,555,9970127,664,146
提取法定盈余公积008,499,97100
提取法定公益金008,499,97100
职工奖金福利00000
提取储备基金00000
提取企业发展基金00000
七、可供股东分配的利润110,038,6740142,556,0560127,664,146
应付优先股股利00000
提取任意盈余公积金00000
应付普通股股利0025,507,20000
转作股本的普通股股利0042,512,000042,512,000
八、未分配利润110,038,674074,536,856085,152,146
恒瑞医药(600276) 利润表
报告期2002-03-312001-12-312001-06-302000-12-312000-06-30
一、主营业务收入148,300,121634,268,948299,570,386484,707,192230,820,967
折扣与折让00000
主营业务收入净额148,300,121634,268,948299,570,386484,707,192230,820,967
主营业务成本62,544,016255,391,928129,735,159226,709,347111,515,226
主营业务税金及附加1,802,3927,807,3603,528,2444,994,2242,233,993
二、主营业务利润83,953,714371,069,660166,306,984253,003,621117,071,749
其他业务利润204,1943,253,3091,187,8304,054,6101,061,106
存货跌价损失00062,130-116,082
营业费用35,122,892168,590,03759,824,042111,794,60242,473,797
管理费用26,267,750107,043,99845,500,29865,038,21831,457,631
财务费用4,712,35210,713,5735,506,5805,945,7904,890,903
三、营业利润18,054,91487,975,36156,663,89474,217,49139,426,605
投资收益1,402,7783,254,4341,617,766-865,936240,000
补贴收入01,064,6393,018,4192,117,4580
营业外收入133,2908,395,4174,166,0798,809,889135,145
营业外支出327,7083,024,3901,820,9122,391,6851,178,046
以前年度损益调整00000
营业外收支净额05,371,027000
四、利润总额19,263,27597,665,46163,645,24681,887,21738,623,704
所得税967,06416,261,56320,482,13616,349,68012,913,744
财政返还00000
少数股东权益72,908248,817318,369266,151153,014
购买日前净利润00000
未确认的投资损失00000
五、净利润18,223,30381,155,08142,844,74065,271,38625,556,946
年初未分配利润064,945,00264,945,00227,024,26535,647,281
调整以前年度损益00000
盈余公积转入00000
住房周转金转入00000
其他转入06,595,864000
六、可分配利润0152,695,947107,789,74292,295,65161,204,227
提取法定盈余公积08,601,21107,032,8250
提取法定公益金08,601,21107,032,8250
职工奖金福利00000
提取储备基金00000
提取企业发展基金00000
七、可供股东分配的利润0135,493,525107,789,74278,230,00261,204,227
应付优先股股利00000
提取任意盈余公积金00000
应付普通股股利010,628,000013,285,0000
转作股本的普通股股利039,855,00039,855,00000
八、未分配利润085,010,52567,934,74264,945,00261,204,227
恒瑞医药(600276) 利润表
报告期1999-12-311998-12-311997-12-31
一、主营业务收入413,929,931363,792,259303,570,800
折扣与折让000
主营业务收入净额413,929,931363,792,259303,570,800
主营业务成本216,243,934205,612,929180,388,983
主营业务税金及附加4,173,7873,122,8262,314,563
二、主营业务利润193,512,210155,056,505120,867,253
其他业务利润533,048958,4731,212,368
存货跌价损失317,800415,000365,000
营业费用66,931,16955,584,32147,032,674
管理费用57,801,71441,806,94432,179,754
财务费用6,737,5609,268,13810,065,806
三、营业利润62,257,01548,940,57532,436,387
投资收益303,75035,36381,013
补贴收入1,072,5163,774,01012,593,727
营业外收入840,953555,784432,572
营业外支出1,763,2451,171,8701,032,161
以前年度损益调整000
营业外收支净额000
四、利润总额62,710,98952,133,86244,511,539
所得税11,061,3148,494,2643,382,402
财政返还000
少数股东权益317,207409,62958,459
购买日前净利润000
未确认的投资损失000
五、净利润51,332,46843,229,96841,070,678
年初未分配利润57,377,19524,349,8120
调整以前年度损益000
盈余公积转入000
住房周转金转入000
其他转入000
六、可分配利润108,709,66367,579,78030,714,944
提取法定盈余公积5,735,9415,101,2933,182,566
提取法定公益金5,735,9415,101,2933,182,566
职工奖金福利000
提取储备基金000
提取企业发展基金000
七、可供股东分配的利润97,237,78157,377,19524,349,812
应付优先股股利000
提取任意盈余公积金000
应付普通股股利30,640,50000
转作股本的普通股股利30,950,00000
八、未分配利润35,647,28157,377,19524,349,812
点击近期部分数据内容 返回页顶